Purpose of review: This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options. Recent findings: New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition. Summary: Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor κB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor κB activation.

Original languageEnglish
Pages (from-to)469-473
Number of pages5
JournalCurrent Opinion in Oncology
Issue number5
StatePublished - Sep 2005


  • Human T cell leukemia/lymphoma
  • Lymphoma
  • T cell leukemia/lymphoma


Dive into the research topics of 'Human T cell lymphotropic virus-associated leukemia/lymphoma'. Together they form a unique fingerprint.

Cite this